Radiation Therapy for Intermediate or Higher Risk Prostate Cancer
This study is looking at a new way to treat prostate cancer that is considered intermediate or higher risk. It combines two types of radiation therapy: High Dose Brachytherapy (where a strong radiation source is briefly placed inside the prostate) and Stereotactic Body Radiation Therapy (SBRT), which is a very focused radiation treatment. The main goal is to see how safe this combination treatment is by tracking any side effects you might experience for up to six months after treatment. You might be able to join if you are a man, at least 19 years old, have been diagnosed with this type of prostate cancer, and haven't had prior treatment for it. The study plans to enroll 53 participants, but its current status is unclear.
- Study design
- This is an interventional study, meaning participants will receive a specific treatment. It aims to enroll 53 men.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be monitored for treatment-related side effects for up to 6 months after treatment begins.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
High-dose Brachytherapy Boost With Stereostatic Body Radiation Therapy to Intermediate or Higher Risk Prostate Cancer
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Michael J Baine, MD · PRINCIPAL_INVESTIGATOR · University of Nebraska
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Number of Participants with Treatment-Related Adverse Eventsbetween the start of treatment up to 6 months post-treatment.
To evaluate acute GI or GU toxicity and patient reported symptoms outcomes of SBRT and HDR brachytherapy boost as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 with a scale of Grade 1 through Grade 5 with Grade 1 being mild and Grade 5 being death. The International Prostate Symptom Score (IPSS) will also be used with a scale of 1 through 35, with 1-7 being mild, 8-19 being moderate, and 20-35 being severe. And the International Index of Erectile Function Questionnaire.